Clinical Trial Update: A Multicenter, Randomized, Double-Blind Parallel-Group, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg Once Daily to Placebo qd for the Resolution of Upper Abdominal Pain in Patients With Symptomatic Gastroesophageal Reflux Disease (sGERD) [Phase 3]

View source ↗

Summary

A Phase 3 multicenter randomized trial evaluating esomeprazole 20 mg once daily versus placebo for the resolution of upper abdominal pain in symptomatic gastroe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• Esomeprazole 20 mg (esomeprazole)

Snippet

Sponsor: AstraZeneca | Conditions: Symptomatic Gastroesophageal Reflux Disease (sGERD) | Phase 3 | Status: COMPLETED